A new drug combo for EGFR positive advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be EGFR positive (a high level of a protein called EGFR on the tumor cells).
- You have tried at least one standard treatment that either didn't work or caused side effects you couldn't handle.
- You have a tumor that can be measured on a scan (like a CT or MRI).
- Your blood counts and organ function (liver, kidneys, etc.) must be within a safe range.
- You cannot have active autoimmune disease, uncontrolled infections, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
This trial tests two new drugs (becotatug vedotin and pucotenlimab) together for advanced biliary tract cancer—a cancer of the bile ducts or gallbladder. The drugs may help if your cancer has a specific marker (EGFR) and has not responded to earlier treatments.
This trial tests two drugs — becotatug vedotin and pucotenlimab — together in people with advanced penile cancer whose tumors show a protein called EGFR. It aims to see if this combination can shrink or slow the cancer.
This trial tests two new drugs (becotatug vedotin and pucotenlimab), sometimes combined with radiation, for advanced non-small cell lung cancer that lacks certain genetic mutations but shows high EGFR protein levels. The drugs work by targeting cancer cells directly and boosting your immune system to fight the cancer.
This trial tests a new combination of two drugs—one targets EGFR on cancer cells, and the other boosts your immune system—for people with advanced stomach or GEJ cancer whose tumors are EGFR-positive and have already tried one prior chemotherapy.
Hear when a new Advanced Refractory Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.